Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01718938 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of Velusetrag in Diabetic or Idiopathic Gastroparesis
A Phase 2 study, sponsored by Theravance Biopharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT01718938 is a Phase 2 study that has completed, run by Theravance Biopharma. The registered enrollment target is 34 participants.
The verdict
NCT01718938, a Phase 2 study, has completed, sponsored by Theravance Biopharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
This is a multicenter, randomized, double-blind, incomplete block, three period fixed sequence crossover, multicenter, placebo-controlled study. The study will assess three oral doses of velusetrag (5 mg, 15 mg, and/or 30 mg) or placebo, administered once daily in three periods of 1-week duration each, with a 1-week washout period between treatment periods, in subjects with diabetic or idiopathic gastroparesis. Study 0093 will evaluate the effect of velusetrag in subjects with diabetic or idiopathic gastroparesis by assessing changes in gastric emptying.
Interventions
- DRUG placebo
- DRUG velusetrag dose 1
- DRUG velusetrag dose 2
- DRUG velusetrag dose 3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2012-12 |
| Est. Completion | 2014-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01718938
The ClinicalTrials.gov registry entry for NCT01718938 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Theravance Biopharma, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which placebo is the first listed.
NCT01718938 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01718938 about?
NCT01718938 is a clinical study titled "Phase 2 Study of Velusetrag in Diabetic or Idiopathic Gastroparesis". This is a multicenter, randomized, double-blind, incomplete block, three period fixed sequence crossover, multicenter, placebo-controlled study. The study will assess three oral doses of velusetrag (5 mg, 15 mg, and/or 30 mg) or placebo, administered once daily in three periods of 1-week duration ea...
What is the current status of trial NCT01718938?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2012-12. Estimated completion is 2014-02.
What interventions are being tested in trial NCT01718938?
The interventions under investigation include: placebo (DRUG), velusetrag dose 1 (DRUG), velusetrag dose 2 (DRUG), velusetrag dose 3 (DRUG).
Who is sponsoring clinical trial NCT01718938?
This trial is sponsored by Theravance Biopharma, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.